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Abstract
Human papillomaviruses (HPV) are oncogenic DNA viruses implicated in squamous cell 
carcinomas of several anatomic sites, as well as endocervical adenocarcinomas. Identification of 
HPV is an actionable finding in some carcinomas, potentially influencing tumor classification, 
prognosis, and management. We incorporated capture probes for oncogenic HPV strains 16 and 18 
into a broader next-generation sequencing (NGS) panel designed to identify actionable mutations 
in solid malignancies. A total of 21 head and neck, genitourinary and gynecological squamous cell 
carcinomas and endocervical adenocarcinomas were sequenced as part of the UNCSeq project. 
Using p16 immunohistochemical results as the gold standard, we set a cutoff for proportion of 
aligned HPV reads that maximized performance of our NGS assay (92% sensitive, 100% specific 
for HPV). These results suggest that sequencing of oncogenic pathogens can be incorporated into 
targeted NGS panels, extending the clinical utility of genomic assays.
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INTRODUCTION
Human papillomavirus (HPV) is a double-stranded DNA virus implicated in pathogenesis of 
squamous cell carcinoma at a variety of anatomic sites, as well as endocervical 
adenocarcinomas and benign warts of skin and mucous membranes.1, 2 Worldwide each 
year, more than 600,000 newly diagnosed cancers, representing nearly 5% of all new 
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malignancies, are attributed to HPV infection.2 While cervical cancers and other 
gynecologic tract malignancies are responsible for much of the global burden of HPV-
related cancer, in recent years, HPV-related carcinomas of other mucosal sites have been 
increasingly recognized as a major public health burden. For instance, in the United States, 
oropharyngeal squamous cell carcinomas are now more commonly associated with HPV 
infection than with smoking, reflecting a major epidemiologic transition in this disease.3 
HPV infection is also implicated in a subset of squamous cell carcinomas arising in perineal 
skin, anus, and genitourinary sites.2, 4
More than 100 HPV strains are defined.5 Sexually-transmitted HPV strains are classified as 
high-risk (strains 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) or low-risk 
based on their observed oncogenicity in cervical tissue.6 These high risk strains may be 
found in dysplasia or in invasive malignancy at other sites, although certain viral strains are 
more frequently implicated at certain anatomic sites and in selected geographic populations. 
Identification of HPV in carcinoma is not only pathophysiologically relevant but also may 
influence management decisions.7 For instance, HPV-associated oropharyngeal squamous 
cell carcinomas are exquisitely radiation sensitive.8 As such, patients may be candidates for 
lower dose radiation therapy protocols with reduced treatment-related morbidity.9 For this 
reason, and because results are also prognostic, practice guidelines now recommend that 
HPV status be determined on all newly diagnosed oropharyngeal carcinomas.10
In clinical laboratories, the methods generally utilized to detect HPV in biopsy and surgical 
resection specimens include p16 immunohistochemistry (IHC), HPV in situ hybridization 
(ISH), and molecular methods such as PCR.10, 11 CDKN2A (p16) is a cyclin-dependent 
kinase inhibitor which is overexpressed in HPV-associated malignancies due to inhibition of 
RB1 by virally-encoded E7 protein.11, 12 Immunohistochemical detection of host p16 
expression provides a robust, albeit indirect, method for localizing HPV infection in 
malignant cells 13–15. However, HPV-independent p16 upregulation can occur, meaning that 
p16 overexpression is not entirely specific for HPV infection.16, 17 Moreover, p16 IHC 
cannot distinguish viral strains. While direct detection of high-risk HPV nucleic acid by ISH 
could theoretically overcome some of these limitations, available HPV ISH assays are 
hampered by inferior test performance and high cost relative to p16 IHC.17, 18 Meanwhile 
alternative molecular assays such as PCR are limited by inability to localize infection to 
malignant cells.11
With the development of massively parallel genome sequencing technology, it is possible to 
comprehensively characterize the mutational spectrum of tumors.19 Numerous clinical 
laboratories now offer next-generation sequencing (NGS) panels to interrogate somatically 
mutated genes implicated in tumorigenesis or predicting response to therapy. We explored 
incorporating viral capture probes into such a panel to provide a new method for detecting 
and subtyping oncogenic viruses like HPV.
UNCseq is a research protocol at the University of North Carolina at Chapel Hill (UNC) 
which aims to identify actionable somatic genomic variants in cancer tissue. Capture probes 
used in this study include conserved sequences of several viruses, including HPV strains 16 
and 18. As of January 2014, 523 tumors had been sequenced, including a total of 21 head 
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and neck, genitourinary and gynecological squamous cell carcinomas and endocervical 
adenocarcinomas. Herein, we report test performance characteristics of our NGS panel for 
HPV detection and demonstrate that incorporating viral capture probes into such panels 
offers a reliable method for identifying and subtyping HPV in tumor tissues.
MATERIALS AND METHODS
Patients and samples
The UNCseq project is UNC’s major research study to establish clinical-grade oncology 
services using NGS technology. The protocol involves sequencing exons of a custom list of 
247 human genes and 10 pathogen genome segments in fixed or frozen cancer tissue and 
matched germline DNA from consenting local patients. All studies were done with approval 
of our Institutional Review Board.
As of January 2014, 523 tumors had been sequenced. In each case, non-malignant tissue 
from the same subject was also sequenced in order to identify somatic changes. 
Gynecologic, head and neck, and genitourinary squamous cell carcinomas and endocervical 
adenocarcinomas (N = 21) are the focus of the current study, as these are the malignancies in 
which HPV has been previously implicated for clinical decision-making.
DNA Isolation, Library Preparation, and Sequencing
A pathologist examined H&E stained slides from each case to confirm the diagnosis and to 
estimate malignant cell proportion. DNA was extracted from fresh frozen tissue samples (16 
cases) or from FFPE tissue sections (5 cases) using either the Gentra Puregene Tissue Kit 
(QIAGEN, Valencia CA) or the Maxwell 16 DNA purification platform (Promega Corp, 
Madison, WI), and then fragmented by sonication. Resultant DNA fragments were then 
subjected to repair and end-polishing (blunt-end or A-overhang), before ligation of custom, 
single-end adapters. Agilent SureSelect Target Enrichment System was used for baited 
capture of pertinent human and viral gene segments (Agilent Technologies, Santa Clara, 
CA). Capture probes were designed to target exons from 247 host genes, as well as ten 
cancer-related pathogens (HPV strain 16, HPV strain 18, Epstein-Barr virus, human 
herpesvirus 8, BK virus, JC virus, human T-lymphotropic virus, Merkel cell polyomavirus, 
and Helicobacter pylori). Relevant to the current work, capture probes incorporate viral 
genome sequence for HPV strains 16 and 18 (GenBank IDs NC_001526 and NC_001357, 
respectively).
During DNA isolation and library preparation, DNA concentration was measured by 
fluorometry, DNA quality was assessed using the Agilent 2100 Bioanalyzer high sensitivity 
DNA assay, and DNA size was determined by Experion automated electrophoresis system 
(BioRad, Hercules CA) or by Agilent TapeStation. Sequencing was then performed using a 
HiSeq2000 sequencer (Illumina Inc, San Diego CA).
NGS Data Analyis
Raw sequence reads were analyzed using the CASAVA v.1.8 package (Illumina) to generate 
FASTQ files, a file format which combines nucleotide sequence data and quality indicators. 
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Using the Burrows-Wheeler Aligner software (BWA v0.6.2) developed to map sequence 
data, reads were then aligned to the reference human genome (build 37, GRCh37) and to 
selected genomic sequences for the ten pathogens listed above, all of which were combined 
into a single concatemerized reference sequence. To decrease problems of misalignment 
caused by insertions/deletions, local realignment and base quality score recalibration were 
performed using the Genome Analysis Toolkit (GATK v2.6) and the GATK resource bundle 
(v2.5)[17]. Filtering was performed by imposing a minimum Phred quality score of read 
mapping (MapQ). Reads with low mapping quality (MapQ < 5) were removed.
HPV Analysis
The number of aligned HPV (strain 16 or 18) reads and total aligned sequence reads were 
recorded for each case. The average number of independent reads aligned at particular 
genomic regions (sequencing depth) varied from sample to sample. In order to adjust for 
variations in sequencing depth, the number of aligned HPV reads was then calculated per 
one million total sequence reads aligned to either the human or pathogen genomes. This 
calculation provides a value reflecting the proportion of all sequence reads that derive from 
HPV for each tumor.
p16 IHC
For cases in which p16 IHC was performed as part of clinical care, slides and relevant 
controls were reviewed. For all other cases, a block of tumor was recut and 
immunohistochemical stains were performed in the UNC Translational Pathology 
Laboratory using a mouse monoclonal anti-p16 antibody (clone E6H4, Ventana, Tucson, 
AZ) and appropriate positive and negative controls. Signal localization to at least 70% of 
malignant cells was interpreted as a positive result.
HPV ISH
ISH for detection of HPV strains 16 and 18 was performed using the Pathogene(R) HPV 
Type 16/18 probe (Enzo Life Sciences, Farmingdale, NY) on a Leica Bond-III instrument 
according to the manufacturer’s instructions with appropriate positive and negative controls. 
Signal localization to malignant cells was interpreted as a positive result.
Statistics
After the number of HPV reads per one million total aligned reads was calculated for all 
cases, mean values for p16-positive and p16-negative samples were compared by an 
unpaired t-test using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).
RESULTS
Characterization of p16 status by immunohistochemistry
A total of 21 head and neck, genitourinary or gynecological squamous cell carcinomas or 
endocervical adenocarcinomas were examined. By IHC, 13 were p16-positive, and 8 were 
p16-negative. Differences in anatomic site of origin were noted between p16-positive and 
p16-negative cases, consistent with the epidemiology of these diseases. Specifically, 11 of 
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12 gynecologic malignancies, 2 of 6 head and neck malignancies, and 0 of 3 genitourinary 
malignancies were p16-positive (Table 1). For these 21 neoplasms, the percent of malignant 
cells input into the sequencing assay ranged from 20 to 90% (mean 51%).
Determination of HPV status by NGS
Given variation in sequencing depth between cases (range = 8.5 – 43 × 106 total aligned 
sequence reads), the number of HPV reads was normalized by calculating the number of 
aligned HPV reads per 106 total aligned sequence reads. Observed normalized values ranged 
from 0 to 39,968 HPV reads per million aligned reads. When cases were stratified by IHC 
results, the mean number of corrected HPV reads was significantly different between p16-
positive cases and p16-negative cases (mean 13,231 versus 0.1 HPV reads per million reads, 
p < 0.0001) (Figure 1). In fact, six of eight p16-negative cases had no aligned HPV 16 or 18 
reads, and the highest corrected value of HPV-aligned reads among p16-negative cases was 
just 0.7 HPV reads/106 total aligned reads. By comparison, the lowest corrected value of 
HPV-aligned reads among p16-positive cases was 3.6, and twelve of thirteen p16-positive 
cases had corrected values greater than 200 HPV reads/106 total aligned reads. Using a 
conservative cutoff of 100 HPV reads per 1 million total aligned reads (see Discussion), the 
sensitivity and specificity of the NGS assay are 92% and 100%, respectively.
HPV status by in situ hybridization
As part of routine clinical care, high risk HPV ISH was performed on five tumors. Although 
p16 and NGS results were concordant in all cases, one p16-positive/NGS-positive case was 
negative by ISH (Table 2), suggesting that the ISH result was false-negative for HPV 
detection (and is further discussed below).
Strain specificity explored by NGS
Distinct HPV16 and HPV18 capture probes are utilized in our platform, and we explored the 
proportion of reads assigned to each reference HPV genome (strain types 16 and 18). In ten 
of thirteen p16-positive cases, all HPV reads aligned to a single strain (Table 3). In the 
remaining three cases, at least 90-fold differences in HPV16 versus HPV18 aligned reads 
were noted. Although we have not excluded coinfection, cross-reactive hybridization, or 
misalignment as causes for ambiguous strain typing, these findings suggest the potential for 
strain assignment based on NGS data analysis.
HPV in unexpected tumor types
As part of the broader UNCSeq project, we examined tumors considered unlikely to be 
HPV-associated based on anatomic site and histopathologic spectrum, and some of these 
tumors had low levels of aligned HPV reads (Figure 2). In this broader group of tumors, the 
neoplasm with the highest HPV level (9.9 HPV reads/106 total aligned reads) was an ovarian 
carcinoma that was demonstrated to be positive for HPV by ISH targeting strains 16/18.
DISCUSSION
Here, we report accurate detection of HPV as part of a broader next generation sequencing 
panel intended to detect actionable somatic variants. This work confirms previous work by 
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Conway et al 20, who used similar methods to demonstrate the utility of NGS methods for 
HPV identification in head and neck cancer. We now extend the utility of NGS to detect 
HPV in cervical and genitourinary cancers, and we demonstrate that sequencing-based 
methods can perform robustly when incorporated into a targeted somatic mutation test panel.
In our study, p16 immunohistochemistry was used as a gold standard to identify HPV -
related tumors. This method is widely employed for surrogate HPV identification in 
anatomic and clinical pathology laboratories, and numerous prior studies have demonstrated 
that p16 IHC is generally equivalent to or superior to competing microscope-based methods, 
such as high risk HPV ISH.17, 18 High risk HPV ISH was performed on five cases in this 
study as part of routine clinical care. Interestingly, although p16 IHC and sequencing results 
were concordant in all cases, one p16-positive/NGS-positive case was negative by ISH 
(Table 2). Although a small sample size, these results suggest that NGS-based HPV 
detection may perform favorably in comparison to other available methods.
Given that there was a five-fold difference in HPV reads reads between the lowest p16-
positive case and the highest p16-negative case, a cut-off of 2 HPV reads/106 would result in 
excellent NGS assay performance with 100% accuracy (100% sensitivity and 100% 
specificity) in this small study. However, as part of the broader UNCSeq project, low HPV 
read counts (<10 per million aligned reads) were occasionally found in tumors considered 
unlikely to be HPV-associated by virture of their anatomic site and histopathologic 
appearance (Figure 2), perhaps reflecting occasional true positive infection of tumor or 
background normal tissue, cross-hybridization of capture probes, or misalignment of 
sequences having homology to the HPV reference sequences. Applying a more conservative 
cut-off of 100 HPV reads per 106 total aligned reads, the assay exhibits 92% sensitivity and 
100% specificity. If these cutoffs are confirmed in larger studies, it may be reasonable to 
omit confirmatory testing in tumors having high (>100) or low (<1) HPV read counts per 
million aligned reads. On the other hand, for cases with intermediate numbers of HPV reads 
(e.g. 1 to 100 reads per 106 reads), p16 IHC may be appropriate as a confirmatory test to 
distinguish infected from uninfected tumors. A suggested algorithm for tiered testing is 
shown in Figure 3.
There are several advantages to an NGS assay for viral detection. First, although p16 IHC is 
much less expensive than NGS, there is minimal additional cost requred to incorporate viral 
capture probes and accompanying bioinformatic analysis into a somatic mutation panel that 
is otherwise used as part of routine clinical care. NGS findings may limit the number of 
IHC, ISH, or other ancillary test methods that are required. Second, sequencing-based 
methods might simultaneously identify and subtype relevant oncogenic viruses. Although 
we have not confirmed the accuracy of strain assignments made with our assay, the tendency 
for sequence reads to align to either HPV16 or HPV18 is promising in this regard. Third, 
targeted therapy for HPV infection and its associated biochemical pathways is being 
explored,21 making it all the more important to accurately identify HPV-infected tumors. 
Finally, capture probes and reference sequences for additional strains can be incorporated 
into NGS-based assays. The adaptability of NGS technology has several potential 
advantages for patient care and for research. For instance, shifts in prevalence of HPV and in 
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viral strain types in response to HPV vaccination22, 23 could reflect evolving epidemiology 
of pertinent malignancies.
Before HPV detection by next-generation sequencing is incorporated into routine clinical 
care, additional study is warranted. Future studies should evaluate lesions infected by non-
oncogenic HPV strains, such as the low risk strains 6 and 11, to evaluate possible cross 
reactivity/misalignment with their high risk counterparts. Although we did not explore the 
minimum tumor content required for accurate HPV result interpretation, it is likely that this 
variable impacts quantitative results for HPV, and future studies should explore the 
minimum tumor content required for accurate HPV detection. Similarly, HPV DNA copy 
number can vary from 1 to over 100 viral genomes per tumor cell, and it may be useful to 
clarify how such variation influences assay performance. Other relevant variables include 
measures of DNA quality and quantity, and the depth of coverage at pertinent loci. Such 
quality indicators and limits of acceptability need to be established.
This study extends the potential utility of NGS sequencing panels in routine pathologic 
evaluation of tumor specimens. Our success in identifying HPV in routinely collected tumor 
samples has implications for the pathogenesis, prognosis, and treatment of several types of 
malignancy known to be associated with oncogenic viruses. Emerging genomic studies 
suggest that pathogens may be implicated in more tumors than was historically 
appreciated.24 Extension to other oncogenic viruses, such as EBV, HHV8, HTLV1, HBV, 
and Merkel cell polyomavirus, should be explored. Evaluation of premalignant lesions is 
also feasible.25
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Figure 1. HPV sequence reads in p16-positive and -negative tumors
Vertical scatter plot demonstrating number of HPV reads per one million total aligned reads 
in p16-positive (n=13) and p16-negative (n=8) tumors. Solid circles: gynecological (GYN) 
squamous cell carcinoma; solid diamonds: endocervical adenocarcinoma; solid squares: 
head and neck squamous cell carcinoma; open circles: genitourinary squamous cell 
carcinomas. Mean values are indicated by horizontal lines (p16-positive = 13,231; p16-
negative = 0.1; p < 0.0001). Only one tumor fell in the grey zone between 1 and 100 HPV 
reads per million aligned reads.
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Figure 2. HPV sequence reads in tumors from anatomic sites without a strong HPV association
Vertical scatter plot demonstrates the number of HPV reads per one million aligned reads in 
500 tumors unlikely to be HPV-associated based on anatomic site and histopathologic 
spectrum (i.e. all tumors in the UNCseq project other than the 21 endocervical 
adenocarcinomas and oropharyngeal, gynecological and genitourinary squamous cell 
carcinomas included in this study). The mean value (0.31 HPV reads per one million aligned 
reads) is indicated by the horizontal bar. The highest value (9.9 HPV reads per one million 
aligned reads) was seen in an ovarian serous carcinoma which was confirmed as HPV-
positive by HPV 16/18 in situ hybridization.
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Figure 3. Proposed 2-step algorithm for HPV testing of tumor tissue by next generation 
sequencing
A proposed algorithm incorporates sequencing data to assess HPV status using capture 
probes and a reference sequence that is appropriate to actionable HPV strains for a given 
tumor type. In cervical cancer, such an algorithm should include all 14 high risk strains of 
HPV, whereas the pertinent strain types are less well defined for oropharyngeal and other 
genitorurinary sites. Based on the scenario and data generated in the current study, sequence-
positive tumors (defined by greater than 100 HPV reads per one million total aligned reads) 
and sequence-negative cases (defined by less than 1 HPV read per one million total aligned 
reads) may not require histochemical confirmation. On the other hand, tumors with 
intermediate results between 1 and 100 HPV reads per one million total aligned reads should 
reflex to p16 IHC or to HPV ISH for purposes localizing potential HPV infection to 
neoplastic cells. Further work is required to refine such an algorithm to fit the clinical 
scenario, population, specimen type, and test system.
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Table 1
p16 status and tumor type
Tumor type p16 positive cases
(n = 13)
p16 negative cases
(n = 8)
Gynecologic squamous cell carcinoma 6 1
Endocervical adenocarcinoma 5 0
Head and neck squamous cell carcinoma 2 4
Genitourinary squamous cell carcinoma 0 3
Histologic type and site of origin for 21 tumors stratified by p16 immunohistochemistry.
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Table 2
Concordance between p16 immunohistochemistry, HPV 16/18 in situ hybridization, and HPV 16/18 next 
generation sequencing results
NGS positive
HPV 16/18 ISH positive
NGS positive
HPV 16/18 ISH negative
NGS negative
HPV 16/18 ISH negative
p16 IHC positive (n = 4) 3 1 0
p16 IHC negative (n = 1) 0 0 1
p16 immunohistochemistry (IHC), high risk HPV in situ hybridization (ISH), and next generation sequencing (NGS) results for five cases included 
in this study. Cases with greater than 100 HPV reads / 106 total aligned sequenced reads were considered NGS positive.
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Table 3
HPV strain typing by next generation sequencing
Case HPV16 reads/
106 total aligned reads
HPV18 reads/
106 total aligned reads
Endocervical adenocarcinoma 0 208
Endocervical adenocarcinoma 6.1 540
Cervical squamous cell carcinoma 3.6 0
Head & neck squamous cell carcinoma 821 0
Cervical squamous cell carcinoma 2495 0
Vulvar squamous cell carcinoma 2938 0
Cervical squamous cell carcinoma 6520 0
Vulvar squamous cell carcinoma 11086 0
Endocervical adenocarcinoma 11961 0
Head & neck squamous cell carcinoma 27390 0
Endocervical adenocarcinoma 32804 0.2
Endocervical adenocarcinoma 35165 0
Vulvar squamous cell carcinoma 39968 0.1
Corrected numbers of HPV16 and HPV18 reads (HPV reads / 106 total aligned reads) for the 13 p16-positive tumors included in this study.
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